Clearside Biomedical, Inc. announced on March 20, 2025, that it presented findings on its lead clinical program, CLS-AX, a suprachoroidal injectable suspension of axitinib, at the 2025 Wet AMD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback